NEW YORK, April 7, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Dr. Reddy's Laboratories Ltd. (NYSE: RDY), ICON plc (NASDAQ: ICLR), Endocyte, Inc. (NASDAQ: ECYT), BioScrip Inc. (NASDAQ: BIOS), and DepoMed Inc. (NASDAQ: DEPO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Dr. Reddy's Laboratories Ltd. Analyst Notes

On March 27, 2014, Dr. Reddy's Laboratories Ltd. (Dr. Reddy's) announced the launch of Amlodipine Besylate and Atorvastatin Calcium Tablets, a therapeutic equivalent generic version of CADUET tablets, in the US market on March 17, 2014, following its U.S. FDA approval. Dr. Reddy's Amlodipine Besylate and Atorvastatin Calcium Tablets are available in bottle counts of 30 and 90. According to IMS Health, the CADUET(R) tablets brand and generic had U.S. sales of approximately $163 Million MAT for the most recent twelve months ended January 2014. The full analyst notes on Dr. Reddy's Laboratories Ltd. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/RDY/report.pdf

--

ICON plc Analyst Notes

On March 31, 2014, ICON plc, (ICON) announced that it has agreed to acquire Aptiv Solutions for $143.5 million. According to the Company, Aptiv Solutions is a recognized leader in the design and execution of adaptive clinical trials for pharmaceutical and biotech customers. Commenting on the acquisition, Dr. Nuala Murphy, President, ICON Clinical Research Services, said, "ICON's market-leading innovation is helping our customers to reduce the time and cost of drug development. We are achieving this through the combination of our industry expertise and enabling technologies such as ICONIK and Firecrest. Aptiv Solutions' adaptive trial capabilities will further differentiate and enhance our services to help our customers identify the most promising drug candidates earlier. Their presence in Japan will also broaden our existing capabilities in this market." The full analyst notes on ICON plc are available to download free of charge at:

http://www.AnalystsReview.com/04072014/ICLR/report.pdf

--

Endocyte, Inc. Analyst Notes

On April 2, 2014, Endocyte, Inc. (Endocyte) announced the closing of its underwritten public offering of approximately 5.2 million shares of its common stock at a price to the public of $21.00 per share. This includes the full exercise by the underwriters of their option to purchase c. 0.7 million additional shares. The Company informed that it has received net proceeds of approximately $101.8 million from the offering. The full analyst notes on Endocyte, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/ECYT/report.pdf

--

BioScrip Inc. Analyst Notes

On April 1, 2014, BioScrip, Inc. (BioScrip) announced that it has completed its previously announced sale of substantially all of its Home Health Business, the Deaconess HomeCare to LHC Group, Inc. in a deal valued at approximately $60 million. "With the completion of the Home Health transaction, we now have additional financial flexibility to continue building on BioScrip's solid foundation in home infusion services," said Rick Smith, President and CEO of BioScrip. "We continue to position BioScrip as a leader in the home infusion industry. We look forward to optimizing the value of our assets while maintaining our reputation for clinical excellence." BioScrip intends to use the net proceeds to pay down a part of its outstanding debt. The full analyst notes on BioScrip Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/BIOS/report.pdf

--

DepoMed Inc. Analyst Notes

On March 12, 2014, Depomed, Inc. (Depomed) reported its Q4 2013 and full-year 2013 financial results. For the quarter, revenues came in at $40.6 million, compared to $26.6 million in Q4 2012. Net income totaled $41.8 million, or $0.72 per share, compared with a net loss of $3.7 million, or $0.07 per share, in Q4 2012. For full year 2013, total revenues were $134.2 million compared to $90.8 million in 2012. Net income stood at $43.3 million, or $0.75 per share, compared to a net loss of $29.8 million, or $0.53 per share, in 2012. Net income for the quarter and full year 2013 included a $39 million income tax benefit related to the reversal of the valuation allowance on its deferred tax assets The Company anticipates full-year 2014 revenue to range from $200 million to $215 million and GAAP EPS to range between $0.21 and $0.36 per share. The full analyst notes on DepoMed Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04072014/DEPO/report.pdf

--

About Analysts Review We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 


        
        - This is not company news. We are an independent source and our views do
          not reflect the companies mentioned.
        - Information in this release is fact checked and produced on a best efforts
          basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human
          and are prone to make mistakes. If you notice any errors or omissions, please notify
          us below.
        - This information is submitted as a net-positive to companies mentioned, to
          increase awareness for mentioned companies to our subscriber base and the investing
          public.
        - If you wish to have your company covered in more detail by our team, or wish
          to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
        - For any urgent concerns or inquiries, please contact us at compliance [at]
          AnalystsReview.com.
        - Are you a public company? Would you like to see similar coverage on your
          company? Send us a full investors' package to research [at] AnalystsReview.com for
          consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

http://AnalystsReview.com

SOURCE Analysts Review